← Back to Screener
Decoy Therapeutics Inc. Common Stock (DCOY)
Price$5.89
Favorite Metrics
Price vs S&P 500 (26W)-94.49%
Price vs S&P 500 (4W)-29.29%
Market Capitalization$3.13M
All Metrics
Book Value / Share (Quarterly)$132.84
Cash Flow / Share (Quarterly)$-108.89
Price vs S&P 500 (YTD)-28.32%
Gross Margin (TTM)48.62%
Net Profit Margin (TTM)-179.05%
EPS (TTM)$-593.80
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-593.80
EPS (Annual)$-5.79
ROI (Annual)-321.56%
Gross Margin (Annual)48.61%
Net Profit Margin (5Y Avg)-1270.39%
Cash / Share (Quarterly)$241.60
ROA (Last FY)-184.45%
EBITD / Share (TTM)$-557.08
ROE (5Y Avg)-195.30%
Operating Margin (TTM)-179.62%
Cash Flow / Share (Annual)$-108.89
P/B Ratio0.53x
P/B Ratio (Quarterly)0.71x
Net Income / Employee (Annual)$-3
ROA (TTM)-239.75%
EPS Incl Extra (Annual)$-5.79
Current Ratio (Annual)2.13x
Quick Ratio (Quarterly)2.07x
3-Month Avg Trading Volume0.14M
52-Week Price Return-95.17%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)1.70x
Asset Turnover (Annual)0.05x
52-Week High$415.80
Operating Margin (5Y Avg)-1288.41%
EPS Excl Extra (Annual)$-5.79
26-Week Price Return-87.61%
Quick Ratio (Annual)2.07x
13-Week Price Return-48.96%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.13x
Enterprise Value$-7.577
Asset Turnover (TTM)0.13x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-693.85%
Cash / Share (Annual)$241.60
3-Month Return Std Dev97.12%
Net Income / Employee (TTM)$-6
ROE (Last FY)-368.77%
EPS Basic Excl Extra (Annual)$-5.79
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-593.80
Receivables Turnover (Annual)0.00x
ROI (TTM)-336.35%
P/S Ratio (TTM)0.67x
Pretax Margin (5Y Avg)-1270.40%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-129.80%
Year-to-Date Return-24.39%
5-Day Price Return-5.00%
EPS Normalized (Annual)$-5.79
ROA (5Y Avg)-130.27%
Net Profit Margin (Annual)-693.85%
Month-to-Date Return-9.81%
EBITD / Share (Annual)$-5.96
Operating Margin (Annual)-696.28%
ROI (5Y Avg)-183.25%
EPS Basic Excl Extra (TTM)$-593.80
P/B Ratio (Annual)0.71x
Inventory Turnover (TTM)1.39x
Pretax Margin (TTM)-179.05%
Book Value / Share (Annual)$132.84
Price vs S&P 500 (13W)-51.34%
Beta0.36x
Revenue / Share (TTM)$0.00
ROE (TTM)-340.06%
52-Week Low$5.40
Analyst Recommendations
Oct 2024
Nov 2024
Dec 2024
Jan 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DCOYDecoy Therapeutics Inc. Common Stock | 0.67x | — | 48.62% | — | $5.89 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Decoy Therapeutics is a preclinical-stage biotechnology company developing peptide conjugate therapeutics for respiratory viruses and gastrointestinal cancers. The company combines machine learning and artificial intelligence with high-throughput synthesis to accelerate drug discovery and candidate optimization.